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All possible isomers of N-b-D-glucopyranosyl aryl-substituted oxadiazolecarboxamides were synthesised.
O-Peracetylated N-cyanocarbonyl-b-D-glucopyranosylamine was transformed into the corresponding
N-glucosyl tetrazole-5-carboxamide, which upon acylation gave N-glucosyl 5-aryl-1,3,4-oxadiazole-2-
carboxamides. The nitrile group of the N-cyanocarbonyl derivative was converted to amidoxime which
was ring closed by acylation to N-glucosyl 5-aryl-1,2,4-oxadiazole-3-carboxamides. A one-pot reaction
of protected b-D-glucopyranosylamine with oxalyl chloride and then with arenecarboxamidoximes fur-
nished N-glucosyl 3-aryl-1,2,4-oxadiazole-5-carboxamides. Removal of the O-acetyl protecting groups
by the Zemplén method produced test compounds which were evaluated as inhibitors of glycogen
phosphorylase. Best inhibitors of these series were N-(b-D-glucopyranosyl) 5-(naphth-1-yl)-1,2,
4-oxadiazol-3-carboxamide (Ki = 30 lM), N-(b-D-glucopyranosyl) 5-(naphth-2-yl)-1,3,4-oxadiazol-2-car-
boxamide (Ki = 33 lM), and N-(b-D-glucopyranosyl) 3-phenyl-1,2,4-oxadiazol-5-carboxamide (Ki = 104 -
lM). ADMET property predictions revealed these compounds to have promising oral drug-like
properties without any toxicity.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Glycogen phosphorylase (GP), the main regulatory enzyme of
the glycogen metabolism pathway, is a validated target to control
50 hepatic glucose output in noninsulin dependent or type 2 diabetes
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based inhibitors targeting the catalytic site are the most
extensively investigated derivatives14–17 and a glucopyranosylid-
ene-spiro-thiohydantoin has been shown to have appreciable
in vivo hypoglycaemic effects.18
N-Acyl-b-D-glucopyranosylamines19–21 (Chart 1, I), N-aryl-13
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30 July 2013mellitus (T2DM).1–3 T2DM is a major concern to public health4
with several long term complications6 such as cardiovascular dis
ease, neuropathy, retinopathy and nephropathy. Biochemical an
pharmacological aspects of T2DM have been amply reviewed an
for a detailed rationalization of the possible use of GP inhibitor
(GPIs) as antidiabetics, the reader is kindly referred to those art
cles.1–3 Besides T2DM, inhibition of GP has also been studied i
connection with diseases caused by abnormalities in glycoge
metabolism,7,8 such as myocardial ischemia9, cerebral ischemia1
and tumors.11,12
Several types of compounds have been shown to inhibit th
enzyme under in vitro conditions.13 Among them the glucos
0968-0896/$ - see front matter  2013 Elsevier Ltd. All rights reserved.
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Please cite this article in press as: Polyák, M.; et al. Bioorg. Med. Cheand N-acyl-N0-b-D-glucopyranosyl ureas (II)13,22,23 are among th
best glucose analogue inhibitors of GP discovered to date, whic
are efﬁcient in or below the low micromolar range.
Bioisosteric replacement is widely used in medicinal chemistr
to design new drug molecules by systematic modiﬁcation of lea
compounds.29 Nonclassical bioisosteric replacements of the NHC
moiety in I by heterocyclic linkers A–D (Chart 1) resulted in inhib
itors of varying efﬁciency.24–26 While 1,2,3-triazoles IA prove
equipotent with the amides I, among oxadiazoles IB–D the const
tution of the ring was decisive for the effect, and only ID was o
similar efﬁciency as I. In these compounds the presence of a larg
hydrophobic aromatic ring was very advantageous for the inhib
tion, and derivatives with a 2-naphthyl group were the best inhib
itors in each series. Replacements of the ‘second’ amide moiety in
(highlighted in Chart 1) with heterocycles E and F were detrimen
tal for the binding, but revealed that compounds with a phenym. (2013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
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Ploup could bind stronger than those with a 2-naphthyl
bstituent.28
OPG
PGO
PGO N Z
O Z: group for hete
SchemAs a continuation of our systematic structure–activity relation-
ip studies25,26,28,30 on bioisosteric replacements of NHCO moie-
s in inhibitors I and II, we have now synthesised new
adiazolecarboxamide derivatives IIB–D and evaluated through
etic experiments their potential for GP inhibition. In addition,
ediction of absorption, distribution, metabolism, excretion and
xicity (ADMET) properties was also performed to evaluate the
ug-like potential of these derivatives.
Results and discussion
. Syntheses
Preparation of the target compounds was envisaged and inves-
ated by two possible routes (Scheme 1): formation of the amide
N bond in a direct transformation of protected glucopyranosyl
ide via acylation of the in situ generated iminophosphorane with
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28
target compounds of this study: 
IIB-D
t rabbit muscle GPb (Ki (lM) for R = 2-naphthyl).suitable functional groups of the corresponding N-acylated
copyranosylamine derivatives (route B).
To study synthetic routes A, preparation of the necessary oxa-
azolecarboxylic acids was ﬁrst attempted. Following a literature
otocol, commercially available benzhydrazide (1) was ethoxaly-
ed to give 2 (Scheme 2) which was closed to ethyl 5-phenyl-
,4-oxadiazole-2-carboxylate (3) in 47% yield.31 Hydrolysis of 3
ve carboxylic acid 4 in 70% yield.32 Synthesis of 1,2,4-oxadiaz-
110-carboxylic acids was also tried from the corresponding ethyl
ters,33 however, we were unable to reproduce the reported
drolytic step34 because of opening of the heterocycle.
Acylation of the glycosylimino-trimethylphosphorane obtained
m 2,3,4,6-penta-O-acetyl-b-D-glucopyranosyl azide (6) with car-
xylic acid 4 failed, however, oxadiazolecarboxamide derivative
a could be prepared in 10% yield by using acid chloride 5.
In view of the low yield of this transformation and the failure of
tting other oxadiazolecarboxylic acids, we turned to the
013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
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Scheme 2. (i) EtOCOCOCl, 3 equiv Et3N, CH2Cl2, 0 C to rt and in the same pot (ii)
toluene, 50 C; (vii) Me3SiN3, Bu2SnO; dry toluene 80 C; (viii) ArCOCl, dry toluenpreparation of our target compounds by route B (Scheme 1). N-
Cyanocarbonyl-2,3,4,6-penta-O-acetyl-b-D-glucopyranosylamine
(8, Scheme 2) was the key intermediate of this pathway, which was
prepared from glucosylamine 7 in 57% yield by using Renslo’s
method.35 Transformation of 8 into N-glucopyranosyl tetrazol-5-
carboxamide 9 was achieved with Me3SiN3–Bu2SnO36 in 88% yield.
The necessary 5-aryl-1,3,4-oxadiazole derivatives 10a–c were ob-
tained from 9 by the corresponding aroyl chloride in dry toluene
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Scheme 4. (i) (COCl)2 in dry THF at 0 C; (ii) amidoximes 18a–c, TH
Scheme 3. (i) NH2OHHCl; dry pyridine; 50 C; (ii) 1. ArCOCl, dry pyridine–toluene,
110 C; (iii) TBAF in THF-dry toluene, 110 C; (iv) NaOMe (cat.), dry MeOH.
Please cite this article in press as: Polyák, M.; et al. Bioorg. Med. Cheat elevated temperature37 in moderate to good yields (10a: 80%
10b: 74%, 10c: 30%). O-Deacetylations were performed by th
Zemplén protocol to give excellent yields (up to 87%) of unpro
tected 1,3,4-oxadiazole derivatives 11a–c.
Next, we turned to the synthesis of N-glucopyranosyl 5-ary
1,2,4-oxadiazole-3-carboxamides 15a–c (Scheme 3). In a continu
ous operation, N-cyanocarbonyl derivative 8 was transformed int
amidoxime 12 by NH2OH, followed by acylation with aroyl chlo
rides and ring closure in the presence TBAF to the desired 1,2,4-oxa
diazole derivatives 14a–c in moderate overall yields (22–24%
Synthesis of 14awas also carried out via the isolated but unpuriﬁe
12 and fully characterized 13a in a two steps procedure, but th
overall yield was similar (28% as compared to 24% by the one-po
reaction). O-Deacetylations by the Zemplén protocol gave th
unprotected 5-aryl-1,2,4-oxadiazole derivatives 15a–c in accep
able yields (49–64%).
Synthesis of N-glucopyranosyl 3-aryl-1,2,4-oxadiazole-5-car
boxamides 20 was attempted by cycloaddition of nitrile-oxides t
the CN group of 8, however, this resulted in an unseparable mult
component product mixture. To get 20 in a less direct but one-po
procedure, acylation of glucopyranosylamine 7 was achieved wit
(COCl)2 in dry THF (Scheme 4) to give the N-substituted oxamidoy
chloride 16. Next, freshly prepared arenecarboxamidoximes 18a
c,38–40 obtained from the corresponding nitriles 17a–c, wer
acylated by 16 to furnish 19a–c which underwent immediate rin
closure to the desired 3-aryl-1,2,4-oxadiazole-5-carboxamide
20a–c in low to acceptable yields (15–55%). O-Deacetylations wer
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m. (2013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
performed by the Zemplén protocol to give good (62–79%) yields of
unprotected 3-aryl-1,2,4-oxadiazole derivatives 21a–c.
2.2. Enzyme inhibition studies
The kinetic parameters of the deprotected compounds (inhibi-
tion constants (Ki) against rabbit muscle glycogen phosphorylase
b (RMGPb)) were determined according to the protocol described
160 earlier.41 The results are summarized in Table 1, together with
the Ki-s of relevant reference compounds.
The new N-glucopyranosyl oxadiazole-carboxamides showed
inhibitory properties in a very broad range from inactive com-
pounds to low micromolar inhibitors. The most remarkable obser-
vation was that the best compounds in the different series did not
have the same aromatic moiety as it could have been expected
from previous experiences. Thus, from 1,3,4-oxadiazoles 11, from
5-aryl-1,2,4-oxadiazoles 15, and from 3-aryl-1,2,4-oxadiazoles 21,
the 2-naphthyl 11b, the 1-naphthyl 15c, and the phenyl 21a deriv-
170 atives, respectively, were the best inhibitors. Since the size of the
heterocycles must be very similar, this phenomenon might be
due to variations of interactions between the oxadiazole rings
and the enzyme as well as to the probably different orientations
of the aromatic substituents. It is also worth noting that in two ser-
ies the 2-naphthyl derivatives 15b and 21bwere inactive, although
this was similar to the cases of isoxazoles 22 and 1,2,3-triazoles 23.
In comparison to the homoaromatic N-glucopyranosyl arenecarb-
oxamides 24 the inhibition of the oxadiazolecarboxamides was
generally weaker for the phenyl (a) and the 2-naphthyl (b) deriva-
180 tives, while stronger for the 1-naphthyl (c) compounds. This may
be attributed to the different size of the molecules and the orienta-
tion of the aromatic rings. Finally, a comparison to the ‘parent’
molecules 25 used as lead for the bioisosteric replacement showed
a signiﬁcant loss of the activity with each of the aromatic substit-
uents. Molecular dockings to get a better insight in the structural
de
N-
str
2.3. ADMET properties calculations
190Unfavourable absorption, distribution, metabolism, excretion
and toxicity (ADMET) properties can in many cases lead to the clin-
ical trials failure of otherwise potentially successful drug
candidates. Their evaluation, therefore, at an earlier stage is
desired.43,44 Accordingly, we have predicted ADMET properties of
our inhibitors using the QikProp 3.5 program (Schrodinger, LLC)
which estimates both physically signiﬁcant descriptors and phar-
maceutically relevant properties. Considering the reported accu-
racy of ALOGPS45 in comparison with other programs,46 log S
(aqueous solubilities) and log P(o/w) (partition of ligands in an oct-
200anol/water mixture) values from ALOGPS 2.1 are also reported.
Meanwhile, toxicity is the leading cause of drug attrition in clinical
trials, together with lack of efﬁcacy.47 Therefore, toxicity structural
warnings for our inhibitors were also probed using the FAF-Drugs2
server.48
The results of our calculations are given in Table 2. Property pre-
dictions that are outside the range observed for 95% of known drugs
(QikProp, version 3.5, User Manual) are ﬂagged with an asterisk (⁄),
while violations of Lipinski’s ‘rule of ﬁve’49 Jorgensen’s ‘rule of
three’50,51 (QikProp 3.5 User Manual) for oral bioavailability are
210highlighted in italics. The property values should be treated as
approximate but serve as a useful guideline for future ligand studies,
of particular relevance here.
As a ﬁrst test of the drug-likeness of the ligands, we applied
Lipinski’s ‘rule of ﬁve’ requiring candidates to have no more than
5 and 10 hydrogen bond donors (HBDs) and acceptors (HBAs),
respectively, molecular weights (MW) less than 500 amu, and log
P(o/w) values less than 5. An orally active compound/drug should
have no more than one violation of these rules. No violations of
these rules was observed for any of our inhibitors. Furthermore,
220the properties were within the range of values for 95% of known
drugs. Satisfactory agreement between QikProp and ‘consensus’
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Pltails of the binding peculiarities of these and other heterocyclic
glucopyranosyl carboxamides as well as to predict more efﬁcient
uctures are in progress.
le 1
ibition of rabbit muscle glycogen phosphorylase b (RMGPb) by the new
pounds and selected glucose derivatives Ki (lM)
O
HO
HO
HO
OH
H
N linker
O
Ar
Ar
Linker a b c
N
O
N
11 545a 30 172a
N
N
O
15 136a No inhibitionb 33
O
N
N
21 104 No inhibitionb 145a
O N
22 17228
No
inhibitionb28
—
N
N
N
23 7528
No
inhibitionb28
—
none 24 8120 1020 44420
H
N
O
25 4.613 0.3513 1513
Calculated from the IC50 values by the Cheng–Prusoff equation: Ki = IC50/
+ [S]/Km).42
Zero percentage inhibition at 625 lM.ease cite this article in press as: Polyák, M.; et al. Bioorg. Med. Chem. (2OGPS logP(o/w) values was obtained, with a root-mean-square
viation (RMSD; Eq. (1)) of 1.1 and a maximum absolute differ-
ce of 1.3 units.
Jorgensen’s ‘rule of three’ considers a Caco-2 cell permeability
lue >22 nm s1 (used as a model for gut–blood barrier53, a log
value >5.7 and number of primary metabolites (NPM) <7 to
characteristic of potential drugs with better oral bioavailability,
ore ‘drug-like’ molecules having fewer violations. The log S and
M criteria are satisﬁed for all ligands. The RMSD (Eq. (1)) be-
een QikProp and ALOGPS log S values was 0.6, with a maximum
solute difference of 0.7 units. The Caco-2 cell permeabilities (18–
nm s1), however, are generally borderline the Jorgensen limit
d outside the desirable range of 95% of known drugs
25 nm s1). This is consistent with inhibitor polar surface areas
SAs; 170 Å2) exceeding Veber et al.,52 suggested limit (PSA
40 Å2), but contrary to the PSAs lying within the range for 95%
known drugs (7–200 Å2). It is clear, however, that the sensitive
lance between adequate lipophilicity and solubility properties
ll need attention in ‘lead optimization’ of any heterocylic deriv-
ive conjugated to glucose found to have attractive GP inhibitory
tential (low lM activity or better).
The degree of plasma protein binding also affects the amount of
available drug. LogKhsa is the prediction of the degree of binding
human serum albumin (hsa) and is satisfactory for all ligands
1), within the range for 95% of known drugs (1.5–1.5). Likewise,
e predicted blood–brain barrier co-efﬁcients (logBB values:3.0–
) are within the desirable limits (3.0–1.2). Finally, a complete
k of toxicity structural warnings from FAF-Drugs2 is encouraging
th respect to the toxicity proﬁles for conjugates of glucose and
bstituted heterocycles.48013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
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Synthetic procedures were elaborated for all possible isomers o
N-b-D-glucopyranosyl aryl-substituteD-oxadiazolecarboxamide
The compounds with phenyl, 1- and 2-naphthyl substituents wer
assayed against rabbit muscle GPb to show low micromolar efﬁ
ciency for the best inhibitors. Both the constitution of the oxadiazol
ring and the type of the aryl substituent had a strong bearing on th
inhibition, and the best compounds of the different series were 11
(Ki = 30 lM), 15c (Ki = 33 lM), and 21a (Ki = 104 lM). ADMET prop
erty predictions revealed all ligands to have oral ‘drug-like’ proper
ties based on Lipinski’s ‘rule of 5’. Apart from potential permeabilit
issueswhichwould require ‘optimization’ based on Jorgensens ‘rul
of three’, the inhibitors had satisfactory pharmacokinetic proﬁle
and were devoid of any toxicity structural warnings. The consider
ation of heterocyclic substitutions in N-b-D-glucopyranosyl carbox
amides is thus justiﬁed and further syntheses and computationa
evaluation of such compounds will be reported in due course.
4. Experimental
4.1. General synthetic methods
Melting points were measured in open capillary tubes or on
Koﬂer hot-stage and are uncorrected. Optical rotations were deter
mined with a Perkin–Elmer 241 polarimeter at room temperatur
NMR spectra were recorded with Bruker 360 (360/90 MHz fo
1H/13C) spectrometer. Chemical shifts are referenced to TMS a
the internal reference (1H), or to the residual solvent signal
Microanalyses were performed on an Elementar vario Micro cub
TLC was performed on DC-Alurolle Kieselgel 60 F254 (Merck). TL
Table 2
Results of ADMET property predictions for the inhibitors studied in this worka
Inhibitor Lipinskis’s rule of ﬁve and violations (V)b V Jorgensen’s
Mr (Da) HBDg HBAh LogP (o/w)i Caco-2j (nm
(<500) (65) (610) (<5) (<22)
11a 351.3 5 10 1.4 0 22.3⁄
(0.8 ± 0.7)
11b 401.4 5 10 0.6 0 22.3⁄
(0.3 ± 0.7)
11c 401.4 5 10 0.7 0 21.8⁄
(0.3 ± 0.7)
15a 351.3 5 10 1.6 0 18.5⁄
(0.7 ± 0.5)
15b 401.4 5 10 0.8 0 21.1⁄
(0.4 ± 0.5)
15c 401.4 5 10 0.9 0 21.9⁄
(0.4 ± 0.5)
21a 351.3 5 10 1.6 0 19.4⁄
(0.7 ± 0.5)
21b 401.4 5 10 0.9 0 18.1⁄
(0.4 ± 0.5)
21c 401.4 5 10 0.9 0 20.0⁄
(0.4 ± 0.5)
Rangel 130–725 0–6 2–20 2.0–6.5 — <25 poor; >
a ADMET data were calculated as described in the text using Qikprop 3.5; predi
b Rules as listed in the columns, with any violations of the rules highlighted in
c PSA represents the van der Waals (polar) surface areas of N and O atoms52 r
d LogKhsa: predicted binding to human serum albumin.
e LogBB: the predicted blood–brain barrier co-efﬁcient.
f Toxicity structural warnings from FAF-Drugs2.
g Number of hydrogen bond donors.
h Number of hydrogen bond acceptors.
i Values calculated with ALOGPS are given in parentheses (a ‘consensus’ value
j Caco-2 cell permeability.
k Number of primary metabolites.
l Range for 95% of known drugs; reference: QikProp version 3.5 User’s ManuaPlease cite this article in press as: Polyák, M.; et al. Bioorg. Med. Cheof three and violations (V)b V PSAc (Å2) LogKhsad LogBBe TSWf
) LogSi NMPk
(>5.7) (<7) (<140 Å2)
2.6 6 0 170.7 1.04 2.7 —
(2.0)
3.4 6 0 170.7 0.85 2.8 —
(2.7)
3.3 6 1 171.2 0.85 2.8 —
(2.7)plates were visualized under UV light, and by gentle heating. Fo
column chromatography Kieselgel 60 (Merck, particle siz
(0.063–0.200 mm) was applied.
4.2. 5-Phenyl-1,3,4-oxadiazole-2-carboxylic acid (4)
To the solution of ethyl 5-phenyl-1,3,4-oxadiazole-2-carboxy
ate (3) (1.5 g, 6.91 mmol) in the 1:1 mixture of THF/water (78 mL
LiOH(248mg;10mmol)was addedand stirredat roomtemperatur
for 30min. Then themixturewas acidiﬁedwith cH2SO4 and the pre
cipitated product was ﬁltered off, washed with water and dried o
air. The product is light yellow crystals (900 mg, 68%, mp: decom
posed over 230 C). 1H NMR (DMSO-d6): d (ppm) = 7.5–7.7 (m, 3H
aromatic), 8.0–8.1 (m, 2H, aromatic), 9.1 (s, 1H, COOH). 13C NM
(DMSO-d6): d (ppm): 124.5, 128.23, 130.5, 133.5, 166.15 (aromat
carbons), 178.5 (COOH). Anal. Calcd for C9H6N2O3 (190.04): C
56.85; H, 3.18; N, 14.73; Found: C, 56.94; H, 14.85.
4.3. 5-Phenyl-1,3,4-oxadiazole-2-carbonyl chloride (5)
5-Phenyl-1,3,4-oxadiazole-2-carboxylic acid (4) (400 mg, 2.1
mmol) was dissolved in thionyl chloride (4 mL) and reﬂuxed fo
four hours. Then the mixture was concentrated in vacuum an
used without any puriﬁcation.
4.4. N-Cyanocarbonyl-2,3,4,6-tetra-O-acetyl–D-glucopyranosyl-
amine (8)
To a stirred solution of 2,2-dimethyl-5-(p-tosyloxyimino)-1,3
dioxane-4,6-dione35 (2.19 g, 6.7 mmol) in dry toluene (50 mL
2,3,4,6-tetra-O-acetyl-b-D-glucopyranosylamine (7) (2.35 g, 6.
3.3 5 1 170.4 0.91 2.9 —
(2.7)
3.3 5 1 170.5 0.92 2.8 —
(2.7)
2.6 5 1 171.3 1.10 2.8 —
(2.0)
3.4 5 1 172.4 0.91 3.0 —
(2.7)
3.3 5 1 171.4 0.92 2.9 —
(2.6)
great 6.5–0.5 1–8 — 7–200 1.5–1.5 3.0–1.2 —
properties outside the range for 95% of known drugs are indicated with an asterisk (
lics.
mended PSA <140 Å2.
andard deviation in the case of logP(o/w)).m. (2013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
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Plmol) was added and the mixture was stirred for 2 days at 50 C.
bsequently themixturewas concentrated in vacuum, and the res-
ue puriﬁed by column chromatography (eluent: hexane/ethyl-
etate = 1:1) to give 8 as white crystals. (1.54 g, 57%; [a]D = 9.33
CHCl3; c = 0.51); mp.: 125–145 C). 1H NMR (CDCl3): d (ppm):
2 (3H, s, COCH3), 2.04 (3H, s, COCH3), 2.08 (3H, s, COCH3), 2.10
H, s, COCH3), 3.79–3.88 (1H, m, H-5), 4.10 (1H, dd; J = 1.8 and
.3 Hz; H-6A), 4.29, (1H, dd, J = 4.8 and 12.6 Hz; H-6B), 5.00, 5.08,
9 (3 1H; pseudo t; J = 9.5–9,8; H-2; H-3; H-4), 5.22 (1H, t,
9,2; H-1), 7.86 (1H, d, J = 9.2 Hz, NH). 13C NMR (CDCl3): d (ppm):
.66, 20.78 (4 COCH3), 61.66 (C-6), 67.85; 70.25; 72.58; 74.20;
.92 (C-1, C-2; C-3; C-4; C-5), 110.86 (CN), 143.48 (NHCO),
9.71; 170.05; 170.80; 171.18 (4 CO). Anal. Calcd for
6H20N2O10 (400.11): C, 48.00; H, 5.04; N, 7.00; Found: C: 48.05;
5.09; N: 7.03
. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-2H-tetrazole-
carboxamide (9)
A solution of N-cyanocarbonyl derivative (8) (2.00 g, 5.0 mmol),
methylsilyl azide (2.23 mL, 16.96 mmol) and Bu2SnO (0.10 g,
2 mmol) in anhydrous toluene (90 mL) was stirred overnight
80 C. Subsequently the mixture was concentrated in vacuum,
d the residue was crystallized from methanol to give 9 as white
stals (1.95 g; 88%); mp: 110–113 C; [a]D = 1.61 in CHCl3;
0.335, mp: 174–177 C) white solid. 1H NMR (CDCl3) d (ppm):
3 (3H, s, COCH3), 1.99 (9H, s, COCH3), 3.99 (1H, m, H-5), 4.10
H, dd, J = 12.3, <1, H-6A), 4.24 (1H, dd, J = 12.3, 2.8, H-6B), 5.22,
2, 5.47, 5.66 (4 1H, pseudo t, J = 9.6, 9.1 Hz in each, H-1, H-2,
3, H-4,), 7.26-7.01 (1H, brs, NH), 8.74 (1H, brs, CONH), 13C
R (CDCl3) d (ppm): 20.54 and 20.61 (COCH3), 61.78 (C-6),
.01, 70.42, 73.07, 73.74 (C-2, C-3, C-4, C-5), 77.96 (C-1), 152.59
trazole C-5), 156.97 (amide CO), 169.69, 170.23, 170.47,
0.83 (COCH3). Anal. Calcd for C16H21N5O10 (443.13): C, 43.34;
4.77; N, 15.80. Found: C: 43.39; H: 4.89; N: 15.94.
. General procedures for the preparation of N-(2,3,4,6-tetra-
acetyl-b-D-glucopyranosyl)-5-aryl-1,3,4-oxadiazole-2-
rboxamides
Method A: To a solution of 2,3,4,6-tetra-O-acetyl-b-D-glucopyr-
osyl azide (6, 2.3 mmol) in dry dichloromethane (14 mL) a solu-
n of PMe3 in toluene (2.3 mL) was added and the mixture was
rred at room temperature. When the starting material was
nsformed (TLC, eluent: hexane/ethyl-acetate = 1:1) an acid chlo-
e (2.3 mmol) was added to the mixture and stirred at room tem-
rature for one day. Subsequently the mixture was concentrated
vacuum and the residue was puriﬁed by column chromatogra-
y (eluent hexane/ethyl-acetate = 2:1).
Method B: A solution of an aroyl-chloride (3.37 mmol) and tet-
zole 9 (2.25 mmol) in dry toluene (15 mL) was stirred at 80 C
r 2 h. Then the mixture was cooled and concentrated in vacuum
d the residue was puriﬁed by column chromatography (eluent
xane/ethyl-acetate = 2:1).
. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-5-phenyl-
,4-oxadiazole-2-carboxamide (10a)
By method A, starting from 6 (858 mg, 2.3 mmol) and 5-phenyl-
,4-oxadiazole-2-carbonyl chloride (5) (436 mg, 2.3 mmol) to
e 10a as white crystals (110 mg, 10%).
Bymethod B, starting from benzoyl chloride (196 ll, 1.68 mmol)
d tetrazole 9 (500 mg, 1.12 mmol) in dry toluene (6 mL) to give
a as white crystals (470 mg, 80%, mp: 169–171 C;
]D = 4.672 in DMSO, c = 0.6). 1H NMR (CDCl3) d (ppm): 2.02
H, s, 2 CH3), 2.04, 2.05 (6H, s, 2 CH3), 3.95 (1H, ddd, J = 9.8,ease cite this article in press as: Polyák, M.; et al. Bioorg. Med. Chem. (2and 2.1 Hz, H-5), 4.16 (1H, dd, J = 12.6 and 4.6 Hz, H-6A), 4.28
H, dd, J = 12.6 and 2.1 Hz, H-6B), 5.13, 5.18, 5.36 (3 1H, pseudo
= 9.8, 9.4 and 9.4 Hz, H-2, H-3, H-4), 5.44 (1H, d, J = 9.4 Hz, H-1),
0 (2H, t, J = 7.3 Hz, aromatic), 7.56 (1H, m, aromatic), 8.15 (2H,
J = 7.3 Hz, aromatic). 13C NMR (CDCl3) d (ppm): 20.68 (COCH3),
.79 (3 COCH3), 61.74 (C-6), 68.09, 70.38, 72.90, 73.95 (C-2, C-3,
4, C-5), 78.12 (C-1), 122.69, 127.68, 129.35, 132.95 (phenyl),
3.68, 157.67 (1,3,4-oxadiazole), 166.89 (NHCO), 169.64, 170.11,
0.63, 170.76, (COCH3).
Anal. Calcd for C23H25N3O11 (519.15): C, 53.18; H, 4.85; N, 8.09.
und: C, 53.25; H, 4.96; N, 8.18.
. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-5-(naphth-2-
-1,3,4-oxadiazole-2-carboxamide (10b)
By method B, starting from 2-naphthoyl chloride (640 mg,
7 mmol) and tetrazole 9 (1 g, 2.25 mmol) in dry toluene
5 mL) to give 10b as white crystals (943 mg, 74%, mp: 186–
8 C; [a]D = 12.843 in DMSO, c = 0.61). 1H NMR (CDCl3) d
pm): 2.04 (3H, s, COCH3), 2.06 (6H, s, 2 COCH3), 2.07 (3H, s,
CH3), 3.95 (ddd, J = 10.0, 4.3 and 2.0 Hz, H-5), 5.16, 5.23, 5.40,
9 (4 1H, pseudo t; J = 11.6, 11.3, 9.5, and 9.4 Hz; H-1, H-2, H-
H-4), 4.15 (1H, dd, J = 12.3 and 4.3, H-6A), 4.30 (1H, dd, J = 12.6
d 2.0 Hz, H-6B), 7.54 (2H, m, aromatic), 7.81 (1H, d J = 7.6 Hz;
), 7.88 (2H, t, J = 7.2 Hz; aromatic), 8.09 (2H, m, aromatic),
7 (1H, s, H-1 naphthalene). 13C NMR (CDCl3) d (ppm): 20.67
 COCH3), 61.83 (C-6), 68.24, 70.54, 72.96, 74.05, (C-2; C-3; C-
C-5), 78.29 (C-1), 123.23, 127.39, 128.03, 128.68, 129.12,
9.30, 132.75, 135.19 (aromatic), 153.76, 157.75 (1,3,4-oxadiaz-
), 167.09 (NHCO), 169.59, 170.06, 170.68, 170.98 (COCH3). Anal.
lcd for C27H27N3O11 (569.16): C, 56.94; H, 4.78; N, 7.38. Found: C,
.02; H, 4.86; N, 7.45.
. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-5-(naphth-1-
-1,3,4-oxadiazole-2-carboxamide (10c)
By method B, starting from 1-naphthoyl chloride (178 ll,
7 mmol) and tetrazole 9 (345 mg, 0.78 mmol) in dry toluene
5 mL) to give 10c as white crystals (133 mg, 30%, mp: 124–
6 C; [a]D = 19.64 in CHCl3, c = 0.52). 1H NMR (CDCl3): d
pm) 2.06 (3H, s, COCH3), 2.07 (3H, s, COCH3), 2.08 (3H, s, COCH3),
9 (3H, s, COCH3), 3.98 (1H, ddd, J = 10.2, 4.6 and 2.2 Hz, H-5),
8 (1H, dd, J = 12.6 and 2.2 Hz, H-6A), 4.33 (1H, dd, J = 12.6 and
Hz, H-6B), 5,19; 5,28; 5,43, 5,55 (4 1H, pseudo t, J = 9.7, 9.4,
and 9.3, H-1; H-2; H-3; H-4) 7.46 (1H, m, aromatic), 7.53
H, m, aromatic), 7.66 (1H, m, aromatic), 7.84 (1H, t, J = 8.6 Hz,
omatic), 7.97 (1H, d, J = 8.1 Hz, aromatic), 8.19 (1H, d,
7.3 Hz, aromatic), 8.51 (1H, d, J = 9.2 Hz, CONH). 13C NMR
DCl3): d (ppm) 20.60, 20.70, 20.71 (COCH3), 61.79 (C-6), 68.09,
.41, 72.97, 73.87, (C-2, C-3, C-4, C-5), 78.16 (C-1), 118.99,
4.84, 125.80, 136.88, 128.58, 128.81, 129.52, 129.90, 133.70
romatic), 153.85, 157.19 (1,3,4-oxadiazole), 166.77 (NHCO),
9.61, 170.08, 170.62, 170.70 (COCH3). Anal. Calcd for
7H27N3O11 (569.16): C, 56.94; H, 4.78; N, 7.38. Found: C, 57.04;
4.89; N, 7.46.
0. N-[2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl]-1-(N0-
droxycarbamimidoyl) formamide (12)
To the solution of N-cyanocarbonyl derivative (9) (100 mg,
5 mmol) in anhydrous pyridine (0.5 mL) hydroxylamine hydro-
loride (43.6 mg, 0.63 mmol) was added, and the reaction was
rred for one hour at 50 C. Subsequently it was acidiﬁed with 5%
ueous solution of HCl (10 mL) and extracted with ethyl acetate
 10 mL) and washed with water (2  10 mL) The organic layer013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
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used without any puriﬁcation. (77 mg, 71%).
4.11. N-[2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl]-1-(N0-
benzoyloxycarbamimidoyl) formamide (13a)
A solution of 12 (77 mg, 0.178 mmol), benzoyl-chloride (23 l
0.196 mmol) and anhydrous pyridine (16 ll, 0.196 mmol) in anhy
drous toluene (5 mL) was stirred for 24 h at 40 C. for a day. Subse
quently it was acidiﬁed with 5% aqueous solution of HCl (10 m
and extracted with ethyl acetate (3  10 ml) and washed wit
water (2  10 mL). The organic layer was dried over MgSO4 an
concentrated in vacuum. Puriﬁcation of the residue by colum
chromatography (hexane/ethyl acetate = 1:1) gave 13a as white
crystal (50 mg, 52%, mp: 240–246 C; [a]D = 18.415 in CHCl
c = 0.5). 1H NMR (CDCl3): d (ppm): 2.03 (3H, s, COCH3,), 2.04 (2
3H, s, COCH3), 2.10 (3H, s; COCH3), 3.84 (1H, ddd, J = 10.1, 3.
and 2.2 Hz, H-5), 4.12 (1H, dd, J = 12.4 and 2.2 Hz, H-6A), 4.2
(1H, dd, J = 12.4 and 4.0 Hz, H-6B), 5.08, 5.11, 5.32, 5.33(4 1H
pseudo t; H-1, H-2, H-3; H-4), 5.65 (2H, brs; NH2), 7.47 (2H,
J = 7.2 Hz; aromatic), 7.61 (1H, t, J = 7.2 Hz, aromatic), 7.98 (1H, d
J = 9.5 Hz, NH)8.04 (2H, d, J = 7.2 Hz, aromatic). 13H NMR (CDCl3
d (ppm): 20.07, 20.85 (COCH3); 61.64 (C-6); 68.02, 70.40, 73.03
73.83, 78.34 (C-1, C-2, C-3, C-4, C-5), 128.76, 129.72, 133.63
147.77 (aromatic), 160.08, 163.26, 169.54, 170.15, 170.25, 170.8
(C@N, COPh, COCH3). Anal. Calcd for C23H27N3O12 (537.16): C
51.40; H, 5.06; N, 7.82. Found: C, 51.49; H, 5.15; N, 7.91.
4.12. General procedure for the synthesis of N-(2,3,4,6-tetra-O
acetyl-b-D-glucopyranosyl)-5-aryl-1,2,4-oxadiazole-3-
carboxamides
Method C: To a solution of N-cyanocarbonyl derivative8 (300 m
0.75 mmol) in dry pyridine (1.5 mL) hydroxylamine hydrochlorid
(131 mg, 1.87 mmol) was added and stirred at 50C for 45 min
Dry toluene (10 mL) and 0.76 mmol acid chloride was then adde
and the mixture was reﬂuxed for 1.5 h. Subsequently a solution o
TBAF (0.37 mL of a 1 M solution in THF) was added to the mixtur
and reﬂuxed for seven days (the progress of the reaction was mon
tored by TLC using hexane/ethyl-acetate = 1:1 as eluent). The mix
ture was diluted with 5% aq HCl (30 mL) and extracted with ethy
acetate (3  30 mL), washed with water (2  20 mL) and dried ove
MgSO4. The solvent was evaporated in vacuum and the residue wa
puriﬁed by column chromatography (eluent hexane/ethyl-ace
tate = 1: 1).
4.13. N-(2,3,4,6-Tetra-O-acetyl–D-glucopyranosyl)-5-phenyl-
1,2,4-oxadiazol-3-carboxamide (14a)
To the solution of 13a (80 mg 0.15 mmol) in dry toluene (2 mL)
solution of TBAF (0.37 mL of a 1 M solution in THF)was added to th
mixture and reﬂuxed for four days. Then the mixture was dilute
with 5% aq HCl (30 mL) and extracted with ethyl acetat
(3  30 mL), washed with water (2  20 mL) and dried over mgSO
The solventwas evaporated in vacuum and the residuewas puriﬁe
by column chromatography (eluent: hexane/ethyl-acetate = 1:1) t
give 14a as white crystals (60 mg, 76%, mp: 152–156 C)
By method C, starting from 8 (300 mg, 0.75 mmol), hydroxy
amine hydrochloride (130.8 mg, 1.88 mmol) and benzoyl-chlorid
(0.09 mL, 0.76 mmol) to give 14a as white crystals (96 mg, 24%
mp: 150–157 C; [a]D = 27.07 in CHCl3; c = 0.25). 1H NM
(CDCl3): d (ppm): 2.05 (6H, s; 2 COCH3), 2.07 (3H, s; COCH3
2.10 (3H, s; COCH3), 3.94 (1H, m, C-5), 4.13 (1H, m, H-6A), 4.3
(1H, dd, J = 12.4 and 3.8 Hz, H-6B), 5.14 (2H, pseudo t, J = 9.4 H
H-3, H-4), 5.39; 5.50 (2 1H, pseudo t, J = 9.4 Hz, H-1, H-2), 7.5
(2H, t, J = 7.2 Hz, aromatic), 7.66 (1H, t, J = 7.4 Hz, aromatic), 7.8Please cite this article in press as: Polyák, M.; et al. Bioorg. Med. Che(1H, d, J = 9.4 Hz; CONH), 8.19 (2H, d, J = 7.2 Hz, aromatic). 13
NMR: d (ppm): 20.67, 20.79 (4 COCH3), 61.71 (C-6), 68.1
70.51, 72.75, 73.97 (C-1, C-2, C-3, C-4), 78.10 (C-5), 123.14
128.53, 129.40, 133.77 (phenyl), 156.78 (NHC@O), 162.27 (C-3 i
1,2,4-oxadiazole), 169.66, 170.00, 170.71, 170.88 (4 COCH3
177.34 (C-5 in oxadiazole). Anal. Calcd for C23H25N3O11 (519.15
C, 53.18; H, 4.85; N, 8.09. Found: C, 53.27; H, 4.95; N, 8.19.
4.14. N-(2,3,4,6-Tetra-O-acetyl–D-glucopyranosyl)-5-(naphth-2
yl)-1,2,4-oxadiazol-3-carboxamide (14b)
By method C, starting from 8 (300 mg, 0.75 mmol), hydroxy
amine hydrochloride (130.8 mg, 1.88 mmol) and 2-naphthoyl chlo
ride (157 mg, 0.83 mmol) to give 14b as white crystals (95 mg
22%; mp: 175–180 C; [a]D = 27.102 in CHCl3; c = 0.5). 1H NM
(CDCl3): d (ppm): 2.03 (6H, s, 2 COCH3), 2.04 (3H, s, COCH3
2.06 (3H, s, COCH3), 3.96 (1H, ddd, J = 10.01, 4.5 and 2.0 Hz H-5
4.15 (1H; dd; J = 12.6 and 4.5 Hz H-6A), 4.35 (1H, dd, J = 12.6
4.6 Hz, H-6B), 5.13, 5.14; 5,38; 5,51 (4 1H pseudo t, J = 9.8, 9.5
9.5, 9.4 Hz, C-1; C-2; C-3; C-4), 7.54–7.68 (2H, m, aromatic), 7.9
(2H, d, J = 9.6 Hz), 7.97 (2H, d, J = 8.3 Hz, aromatic and NHCO
8.14 (1H, dd, J = 8.6; 1.6 Hz, aromatic), 8.72 (1H, s, aromatic). 13
NMR (CDCl3): d (ppm): 20.65; 20.76 (COCH3), 61.74 (C-6), 68.12
70.54, 72.79, 73.96 (C-2; C-3; C-4; C-5), 78.80 (C-1), 120.22
123.64, 127.50, 128.06, 129.07, 129.35, 130.02 132.62, 135.57 (aro
matic), 156.82 (NHCO), 163.33 (C-3 in 1,2,4-oxadiazole), 169.64
169.98, 170.68, 170.78 (COCH3), 177.46 (C-5 in 1,2,4-oxadiazole
Anal. Calcd for C27H27N3O11 (569.16): C, 56.94; H, 4.78; N, 7.38
Found: C, 57.02; H, 4.91; N, 7.47.
4.15. N-(2,3,4,6-Tetra-O-acetyl–D-glucopyranosyl)-5-(naphth-1
yl)-1,2,4-oxadiazol-3-carboxamide (14c)
By method C, starting from 8 (300 mg, 0.75 mmol), hydroxy
amine hydrochloride (1308 mg, 1.88 mmol) and 1-naphthoyl chlo
ride (124 ll, 0.83 mmol) to give 14c as white crystals (145 mg, 22%
mp: 175–180 C; [a]D = 27.47 in CHCl3; c = 0.5). 1H NMR (CDCl3
d (ppm): 2.04 (3H, s, COCH3), 2.08 (9H, s, COCH3), 3.94 (1H, m, H-5
4.12 (1H, d, J = 12.4 Hz, H-6A), 4.34 (1H, dd, J = 12.5 and 3.7 H
H-6B), 5.14, 5.16, 5.40, 5.50 (4 1H, pseudo t; J = 9.7 Hz; 1H,
J = 9.7, 9.4 and 9.3 Hz, H-1; H-2; H-3; H-4), 7.55–7.65 (2H, m, aro
matic), 7.72 (1H, t, J = 7.2 Hz, aromatic), 7.93 (1H, d, J = 8.1 Hz, aro
matic), 8.10 (1H, d, J = 9.1 Hz, NHCO), 8.10 (1H, d, J = 8.1 H
aromatic), 8.39 (1H, d, J = 7.3 Hz, aromatic), 9.10 (1H, d, J = 8.6 H
aromatic). 13C NMR (CDCl3): d (ppm): 20.67; 20.72; 20.80 (COCH3
61.73 (C-6), 68.81, 70.58, 72.72, 73.99 (C-2; C-3; C-4; C-5) 78.30 (C
1), 119.51, 130.08, 133.90, 124.95, 125.54, 127.10, 128.90, 129.02
130.77, 134.76 (aromatic), 156.89 (NHCO), 163.14 (C-3 in 1,2,4
oxadiazole), 169.66, 169.99, 170.72, 170.96 (COCH3), 177.47 (C-
in 1,2,4-oxadiazole). Anal. Calcd for C27H27N3O11 (569.16): C
56.94; H, 4.78; N, 7.38. Found: C, 57.03; H, 4.90; N, 7.46.
4.16. General procedure for the synthesis of N-(2,3,4,6-tetra-O
acetyl-b-D-glucopyranosyl)-3-aryl-1,2,4-oxadiazole-5-
carboxamides
Method D: A solution of 2,3,4,6-tetra-O-acetyl-b-D-glucopyrano
sylamine (7, 275 mg, 0.79 mmol) in dry THF (15 mL) was adde
dropwise to the cooled solution of oxalyl chloride (0.79 mmol) i
dry THF (10 mL) in one hour. Subsequently an arene
carboxamidoxime (18a–c, 0.79 mmol) was added to the reactio
mixture and stirring was continued at room temperature for seve
days. The progress of the reaction was monitored by TLC (eluen
hexane/ethyl-acetate = 1: 1). When the reaction was completed
the solvent was removed in vacuum and the residue was puriﬁe
by column chromatography (eluent hexane/ethyl-acetate = 1: 1).m. (2013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
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Pl7. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-3-phenyl-
,4-oxadiazole-5-carboxamide (20a)
By method D, starting from benzamidoxime (18a) (389 mg;
7 mmol) to give 14 as white crystals (845 mg, 55%, mp: 154–
2 C; [a]D = 23.55 in CHCl3; c = 0.5). 1H NMR (CDCl3): d
pm): 2.01 (6H, s, COCH3), 2.02 (3H, s, COCH3), 2.05 (3H, s,
CH3), 3.92 (1H, ddd, J = 10.1, 4.1 and 2.0 Hz, C-5), 4.13 (1H, dd,
12.5, 2.0 Hz, H-6A), 4.42 (1H, dd, J = 12.6, 4.6 Hz, H-6B), 5.10,
1, 5.36, 5.41 (4 1H, pseudo t J = 9.3, 9.7, 9.5 and 9.4 Hz, H-1
2; H-3; H-4), 7.40–7.61 (3H, m, aromatic), 7.9 (1H, d, J =
Hz; NHCO), 8.0–8.1 (2H, m, aromatic). 13C NMR (CDCl3): d
pm): 20.79, 20.68 (COCH3), 61.71 (C-6), 68.14, 70.55, 72.72,
.19 (C-2; C-3; C-4; C-5), 78.42 (C-1), 125.59, 127.78, 129.18,
2.09 (aromatic), 153.31 (C-3 in 1,2,4-oxadiazole), 167.66
HCO), 169.10, 169.61, 169.96, 170.64 (COCH3), 170.85 (C-5 in
,4-oxadiazole). Anal. Calcd for C23H25N3O11 (519.15): C, 53.18;
4.85; N, 8.09. Found: C, 53.29; H, 4.97; N, 8.18.
8. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-3-(naphth-
yl)-1,2,4-oxadiazole-5-carboxamide (20b)
By method D, starting from naphth-2-amidoxime (18b)
33 mg, 1.25 mmol) to give 20b as white crystals (109 mg; 15%,
p: 70–83 C; [a]D = 21.85 in CHCl3; c = 0.5). 1H NMR (CDCl3):
ppm): 2.06 (3H, s, COCH3), 2.07 (6H, s; 2 COCH3), 2.09 (3H, s,
CH3), 3.92 (1H, ddd, J = 9.7, 4.6 and 1.8 Hz, H-5), 4.14 (1H; dd;
12.6 and 1.8 Hz; H-6A), 4.34 (1H, dd, J = 12,6 and 4.6 Hz; H-
), 5.14, 5.15 5.39, 5.46 (4 1H, pseudo t; J = 9.7, 9.7, 9.5 and
Hz, H-1, H-2, H-3, H-4), 7.51–7.69 (2H, m, aromatic), 7.90
H, d, J = 8.8 Hz, aromatic), 7.96 (3H, m, aromatic), 8.14 (1H, d,
8,53 Hz, NHCO), 8.66 (1H, s, aromatic). 13C NMR: d (ppm):
.71, 29.82 (COCH3), 61.72 (C-6), 68.12, 70.58, 72.76, 74.21 (C-
C-3; C-4; C-5), 78.41 (C-1), 122.85, 123.74, 127.16, 128.08,
8.72, 129.16, 130.02, 133.07, 135,08 (aromatic), 153,37 (C-3 in
,4-oxadiazole), 167.68 (NHC@O), 169.26, 169.66, 170.01,
0.71 (COCH3), 170,91 (C-5 in 1,2,4-oxadiazole). Anal. Calcd for
7H27N3O11 (569.16): C, 56.94; H, 4.78; N, 7.38. Found: C, 56.99;
4.83; N, 7.41.
9. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-3-(naphth-
yl)-1,2,4-oxadiazole-5-carboxamide (20c)
By method D, starting from naphth-1-amidoxime (18c)
68 mg, 0.90 mmol) to give 20c as a yellow oil (85 mg; 16%,
]D = 31.53 in CHCl3; c = 0.5). 1H NMR: d (ppm): 2.06, 2.07,
8 (12H, s, 3 COCH3), 3.92–3.97 (1H, ddd, J = 10.1, 4.36 and
0 Hz, H-5), 4.11–4.16 (1H, m, H-6A), 4.34 (1H, dd, J = 9.8 and
4, H-6B), 5.16, 5.41, 5.48 (2H, m; 1H, t, J = 9,5 Hz; 1H, t,
9,3 Hz; H-1; H-2; H-3; H-4), 7.57 (2H, t, J = 3.4 Hz, aromatic),
5 (1H, m, aromatic), 7.92 (1H, d, J = 7.9 Hz, aromatic), 8.02
H, d, J = 8.2 Hz, aromatic), 8.17 (1H, d, J = 9.3 Hz, NHCO), 8.27
H, dd, J = 0.5, 7.2 Hz, aromatic), 8.88 (1H, d, J = 8.5 Hz, aromatic).
NMR: d (ppm): 20.61, 20.66, 20.74 (COCH3), 61.68 (C-6), 68.04,
.49, 72.68, 74.03, 78.32 (C-1, C-2, C-3, C-4, C-5), 122.34, 130.32,
3.88, 125.07, 126.01, 126.62, 128.04, 128.84, 30.03, 132.74 (aro-
atic), 153.39 (NHCO), 166.73 (oxadiazole), 169.32, 169.59,
9.93, 170.62 (COCH3), 170.79 (oxadiazole). Anal. Calcd for
7H27N3O11 (569.16): C, 56.94; H, 4.78; N, 7.38. Found: C, 57.16;
4.88; N, 7.48.
0. General procedure for removal of O-acetyl protecting
oups
Method E: To the solution of a protected sugar derivative in dry
ethanol (or in dry methanol and dry chloroform) a catalyticease cite this article in press as: Polyák, M.; et al. Bioorg. Med. Chem. (2ount of NaOMe (1 M solution in methanol) was added and stir-
d at room temperature. The progress of the reaction was moni-
red by TLC (chloroform/methanol = 9:1). When the starting
aterial was consumed the mixture was neutralised with a cation
change resin Amberlyst 15 (H+ form) or with acetic acid, then the
sin was ﬁltered off and the solvent removed. The precipitated
oduct was ﬁltered off, washed with ether and dried.
1. N-(b-D-Glucopyranosyl)-5-phenyl-1,3,4-oxadiazole-2-
rboxamide (11a)
By method E, staring from 10a (90 mg, mmol) in the mixture of
y methanol (3 mL) and dry chloroform (1.5 mL) gave 11a as a
ite crystal (56 mg, 50%, mp: 229–232 C, [a]D = 7.82 in DMSO;
0.45). 1H NMR (D2O): d (ppm): 4.90 (1H, d, J = 8.7 Hz, H-1),
7–7,78 (m; 3H), 8.04–8.18 (m, 2H), 13C NMR (D2O): d (ppm):
.59 (C-6), 69.43, 71.34, 76.75, 78.62, 79.61 (C-1; C-2; C-3; C-4;
5), 122.34, 127.01, 129.41, 132.71 (aromatic), 153.40, 157.99
,3,4-oxadiazole), 165.02 (NHCO). Anal. Calcd for C15H17N3O7
51.11): C, 51.28; H, 4.88; N, 11.96. Found: C, 51.38, H, 4.96, N,
.01.
2. N-(b-D-Glucopyranosyl)-5-(naphth-2-yl)-1,3,4-oxadiazole-
carboxamide (11b)
By method E, starting from 10b (411 mg, 0.72 mmol) in dry
ethanol (2 mL) to give 11b as white crystals (244 mg, 85%, mp:
9–221 C; [a]D = 8.776 in DMSO; c = 0.69). 1H NMR (DMSO-d6)
(ppm): 3.12 (1H, pseudo t, J = 9.2, Hz, H-3), 3.21–3.31 (4H, m,
2, H-4, H-5, H-6A), 3.69 (1H, d, J = 11.2 Hz H-6B), 4.61 (1H, brs
), 4.96 (1H, d, J = 9.2 Hz, H-1), 5.11 (2H, brs 2 OH), 7.52–7.79
H, m, aromatic), 8.05 (1H, d, J = 7.8 Hz, aromatic), 8.18 (3H, s, aro-
atic), 8.75 (1H, s, aromatic), 9.86 (1H, brs, NHCO). 13C NMR
MSO-d6) d (ppm): 60.9 (C-6), 70.00, 71. 93, 77.44, 79.18, 80.17
-1, C-2, C-3, C-4, C-5), 120.18, 123.23, 127.75, 128.15, 129.20,
9.57, 123.57, 134.74 (aromatic) 158.4, 153.6 (1,3,4-oxadiazole),
5.47 (NHCO). Anal. Calcd for C19H19N3O7 (401.12): C, 56.86; H,
7; N, 10.47. Found: C: 56.94; H, 4.87; N, 10.58.
3. N-(b-D-Glucopyranosyl)-5-(napht-1-yl)-1,3,4-oxadiazole-2-
rboxamide (11c)
Staring from 10c (300 mg, 0.53 mmol) in the mixture of dry
ethanol (7 mL) and dry chloroform (7 mL) gave 11c as a white
stal (185 mg, 87%, mp: 230–234 C; [a]D = 3.84 in DMSO;
0.62). 1H NMR (DMSO-d6) d (ppm):3.07–3.17 (1H, m, H-5),
2–3.20 (2H, m, H-2, H-3), 3.41–3.51 (2H, m, H-4, H-6B), 3.70
H, dd, J = 10.5 and 5.4 Hz, H-6A), 4.55–4.65 (1H, m, OH), 4.95–
5 (2H, m, H-1, OH) 5.10–5.17 (2H, m, OH), 7.59–7.90 (3H, m,
omatic), 8.13 (1H, d, J = 8.0 Hz, aromatic), 8.28 (1H, d, J = 8.2 Hz,
omatic), 8.40 (1H, d, J = 7.3 Hz, aromatic), 9.13 (1H, d, J = 8.5 Hz,
omatic), 9.92 (1H, d, J = 8.7 Hz, NH). 13C NMR (DMSO-d6): d
pm): 62.56 (C-6), 71.27, 73.44, 78.75, 80.25, 81.41 (C-1; C-2; C-
C-4; C-5), 120.61, 126.44, 126.75, 128.16, 129.60, 132.20,
0.69, 131.04, 134.69, 135.16 (aromatic), 155.51, 159.42 (oxadi-
ole), 167.08 (NHC@O). Anal. Calcd for C19H19N3O7 (401.12): C,
.86; H, 4.77; N, 10.47; O, 27.90. Found: C: 56.91; H, 4.86; N,
.56.
4. N-(-D-Glucopyranosyl)-5-phenyl-1,2,4-oxadiazol-3-
rboxamide (15a)
By method E, starting from 14a (132 mg, mmol) in dry metha-
l (2 mL) to give 15a as white crystals (56 mg, 64%, mp: 245–
0 C; [a]D = 8.83 in DMSO; c = 0.5). 1H NMR (DMSO-d6): d
pm): 3.07-3.71 (5H, m, H-2, H-3, H-4, H-5, H-6A), 3.79 (1H, d,013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
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30 July 2013J = 10.8, H-6B), 4.58 (1H, brs; OH), 4.93 (1H, d, J = 8.6 Hz, H-1), 5.0
(1H brs; OH), 7.6–7.8 (3H, m, aromatic), 8.10–8.25 (2H, m, aro
matic), 9.49 (1H, brs; NH). 13C NMR (DMSO-d6): d (ppm): 60.9
(C-6), 69.89, 71.70, 77.45, 79.06, 79.84 (C-1, C-2, C-3, C-4, C-5
122.96, 128.14, 129.74, 133.85 (aromatic), 156.88 (NHCO
164.24, 176.03 (oxadiazole). Anal. Calcd for C15H17N3O7 (351.11
C, 51.28; H, 4.88; N, 11.96. Found: C, 51.40, H, 4.99, N, 12.05.
4.25. N-(-D-Glucopyranosyl)-5-(naphth-2-yl)-1,2,4-oxadiazol-3-
carboxamide (15b)
By method E, starting from 14b (95 mg, 0.17 mmol) in the mix
ture of dry methanol (3 mL) and dry chloroform (1.5 mL) to giv
15b as white crystals (33 mg, 49%, mp: 254–258 C; [a]D = 11.7
in DMSO; c = 0.5). 1H NMR (DMSO-d6): d (ppm): 2.97-3.88 (6H
m, H-2, H-3, H-4, H-5,H-6), 4.58 (1H, m), 4.99 (1H, m, H-1), 5.0
(brm, OH), 7.7 (2H, m, aromatic), 8.05 (1H, m, aromatic), 8.2
(3H, m, aromatic), 8.89 (1H, s, aromatic), 9.48 (1H, brs, NHCO
13C NMR (DMSO-d6): d (ppm): 60.99 (C-6), 69.92, 71.73, 77.44
79.05, 79.85 (C-1, C-2, C-3, C-4, C-5), 120.20, 123.52, 127.65
128.01, 129.16, 129.34, 129.50, 132.33, 135.50 (aromatic), 156.8
(NHCO), 164.30, 176.16 (oxadiazole). Anal. Calcd for C19H19N3O
(401.12): C, 56.86; H, 4.77; N, 10.47. Found: C: 56.99; H, 4.91; N
10.62.
4.26. N-(-D-Glucopyranosyl)-5-(naphth-1-yl)-1,2,4-oxadiazol-3-
carboxamide (15c)
By method E, starting from 14c (170 mg, 0.3 mmol) in the mix
ture of dry methanol (3 mL) and dry chloroform (2 mL) to give 15
as white crystals (64 mg, 54%, mp: 235–237 C; [a]D = 7.68 i
DMSO; c = 0.5). 1H NMR (DMSO-d6): d (ppm): 2.99–3.91; (6H, m
H-2, H-3, H-4, H-5, H-6), 4.58 (1H, brs, H-1), 5.06 (2H, br m, OH
7.74 (3H, m, aromatic), 8.09 (1H, m, aromatic), 8.41 (2H, m, aro
matic), 9.14 (1H, s, aromatic), 9.61 (1H, brs; NHCO). 13C NM
(DMSO-d6): d (ppm): 60.90 (C-6), 69.85, 71.65, 77.40, 79.02
79.82 (C-1, C-2, C-3, C-4, C-5), 119.09, 125.18, 125.33, 127.33
128.68, 128.97, 130.44, 134.40, 129.22, 133.39 (aromatic), 156.8
(NHCO), 164.03, 175.79 (oxadiazole). Anal. Calcd for C19H19N3O
(401.12): C, 56.86; H, 4.77; N, 10.47. Found: C: 56.93; H, 4.91; N
10.61.
4.27. N-(-D-glucopyranosyl)-3-phenyl-1,2,4-oxadiazol-5-
carboxamide (21a)
By method E, starting from 20a (467 mg, 0.9 mmol) in the mix
ture of dry methanol (4 mL) and dry chloroform (4 mL) to give 21
as white crystals (251 mg, 79%, mp: 250–256 C; [a]D = 7.74 i
DMSO; c = 0.5).1H NMR (DMSO-d6): d (ppm): 3.15–3.51 (5H, m
H-2, H-3, H-4, H-5, H-6A), 3.69 (1H, dd, J = 11.5 and 2.0 Hz, H-6B
4.53 (1H, brs, OH),4.92 (1H, brs, OH), 4.93 (1H, d, J = 9.0 Hz, H-1
5.08 (1H bs, OH), 7.66 (3H, m, aromatic), 8.13 (2H, m, aromatic
9.96 (1H, brs, NH). 13C NMR (DMSO-d6): d (ppm): 60.98 (C-6
69.88, 71.70, 77.30, 79.14, 80.11 (C-1, C-2, C-3, C-4, C-5), 125.48
127.25, 129.44, 132.12 (aromatic), 153.57 (NHCO), 168.15
169.15 (oxadiazole). Anal. Calcd for C15H17N3O7 (351.11): C
51.28; H, 4.88; N, 11.96. Found: C, 51.34, H, 4.98, N, 12.03.
4.28. N-(-D-glucopyranosyl)-3-(napht-2-yl)-1,2,4-oxadiazol-5-
carboxamide (21b)
By method E, starting from 20b (90 mg, 0.16 mmol) in the mix-
ture of dry methanol (2 mL) and dry chloroform (1 mL) to give 21b
as white crystals (39 mg, 62%, mp: 256–259 C; [a]D = 2.25 in
DMSO; c = 0.5).1H NMR (DMSO-d6): d (ppm): 3.08–3.19 (1H, m,
H-5), 3.21–3.32 (2H, m, H-2, H-3); 4.41–3.52 (2H, m, H-4, H-6A),
s.
Please cite this article in press as: Polyák, M.; et al. Bioorg. Med. Che3.71 (1H, dd, J = 10.9 and 3.3 Hz, H-6B), 4.59 (1H, brs, OH), 4.9
(1H, d, J = 9.1 Hz, H-1), 4.98; 4.99; 5.12 (3 1H, brs, OH), 7.58
7.75 (2H, m aromatic), 8.04 (1H; d, J = 7.3 Hz, aromatic), 8.1
(3H, s, aromatic), 8.72 (1H, s, aromatic), 10.01 (1H, brs; NHCO
13C NMR (DMSO-d6): d (ppm): 60.99 (C-6), 69.89, 71.74, 77.3
79.15, 80.12 (C-1, C-2, C-3, C-4, C-5), 122.85, 123.33, 127.34
127.94, 128.21, 128.88, 129.26, 132.56, 133.40 (aromatic), 153.5
(NHCO), 168.24, 169.19 (oxadiazole). Anal. Calcd for C19H19N3O
(401.12): C, 56.86; H, 4.77; N, 10.47. Found: C: 56.97; H, 4.88; N
10.55.
4.29. N-(-D-glucopyranosyl)-3-(napht-1-yl)-1,2,4-oxadiazol-5-
carboxamide (21c)
By method E, starting from 20c (127 mg, 0.22 mmol) in the mix
ture of dry methanol (2 mL) and dry chloroform (1 mL) to give 21
as white crystals (64 mg, 72%, mp: 245–250 C; [a]D = 6.17 i
DMSO; c = 0.5). 1H NMR (DMSO-d6): d (ppm): 3.08–3.17 (1H, m
H-5), 3.20–3.32 (2H, m, H-2, H-3); 3.40–3.55 (2H, m, H-4, H-6A)
4.60 (1H, brs, OH), 4.98 (1H, d, J = 9.3 Hz, H-1), 4.99 (1H, br
OH), 5.05–5.20 (2H, brs; 2 OH), 7.69–7.73 (3H, m, aromatic
8.10 (1H, d, J = 7.1 Hz, aromatic), 8.23 (1H, d, J = 7.5, aromatic
8.3 (1H, d, J = 7.5, aromatic), 8.81 (1H, d, J = 7.7 Hz, aromatic
10.05 (1H, brs. NHCO). 13C NMR (DMSO-d6): d (ppm): 60.99 (C
6), 69.89. 71.78. 77.32. 79.18. 80.19 (C-1; C-2; C-3; C-4; C-5
119.56, 122.34, 125.44, 126.79, 128.08, 128.94, 129.70, 132.54
129.76, 133.52 (aromatic), 153.71 (NHCO), 164.03, 175.79 (oxad
azole). Anal. Calcd for C19H19N3O7 (401.12): C, 56.86; H, 4.77; N
10.47. Found: C: 56.99; H, 4.90; N, 10.60.
4.30. General procedure for GP inhibition assay
Glycogen phosphorylase b was prepared from rabbit skeleta
muscle according to the method of Fischer and Krebs54 using 2
mercaptoethanol instead of L-cysteine, and recrystallized at leas
three times before use. The kinetic studies with glycogen phos
phorylase were performed as described previously.41 Kinetic dat
for the inhibition of rabbit skeletal muscle glycogen phosphorylas
by monosaccharide compounds were collected using different con
centrations of a-D-glucose-1-phosphate (4, 6, 8, 10, 12 and 14 mM
and constant concentrations of glycogen (1% w/v) and AM
(1 mM). The enzymatic activities were presented in the form o
double-reciprocal plots (Lineweaver–Burk) applying a nonlinea
data-analysis programme. The inhibitor constants (Ki) were deter
mined by Dixon plots, by replotting the slopes from the Linewe
aver–Burk plots against the inhibitor concentrations. The mean
of standard errors for all calculated kinetic parameters average
to less than 10%.55,56 IC50 values were determined in the presenc
of 4 mM glucose 1-phosphate, 1 mM AMP, 1% glycogen, and vary
ing concentrations of an inhibitor.
4.31. ADMET property predictions
ADMET properties of the inhibitor analogues were predicte
using the QikProp 3.5 program (Schrodinger, LLC) in normal mod
ALOGPS 2.145 was used to calculate supplementary logS and ‘con
sensus’ logP(o/w) values for comparison with the QikProp value
The RMSD between QikProp and ALOGPS values was calculated as:
770
RMSD ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
N
XN
i¼1
ðPQP  PALOGPSÞ2
vuut ð1Þ
where PQP and PALOGPS represent the QikProp and ALOGPS
values, respectively, of a property P. The FAF-Drugs2 server48 was
used to extract any toxicity structural warnings for the ligands.
m. (2013), http://dx.doi.org/10.1016/j.bmc.2013.07.024
Inhibitors were initially prepared for the QikProp calculations
using Maestro and LigPrep (Schrodinger, LLC). Use of more ex-
tended conformations of ligands as input to QikProp can lead to
ADMET property predictions closer to their experimental equiva-
780 lents (QikProp version 3.5, User Manual). Confgen 2.3 (Schrodinger,
LLC), therefore, employing the OPLS-AA (2005) forceﬁeld and the
Generalised Born/Surface Area (GB/SA) continuum model for bulk
solvation effects was used to generate low energy conformations
for each ligand (energy window of 5 kcal/mol). The most extended
conformation was then selected based on the calculated solvent
accessible surface areas (SASAs) using the Schrodinger python
script ‘conformer_geom_extent.py’ and used as input for the AD-
MET property predictions.
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